Zacks Investment Research on MSN
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...
Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...
The All India Institute of Medical Sciences (AIIMS), New Delhi, has opened the form correction window for the INI CET 2026 January session on its official website - aiimsexams.ac.in. Candidates who ...
Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...
Board Meeting Intimation for For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025. - Rediff MoneyWiz, the personal finance ...
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF ...
NRA contribution data is from the 1998 through 2018 Congressional cycles and does not include individual expenditures or communication costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback